Bellicum announces update on clinical hold of U.S. BPX-501 studies
Bellicum announced it has received notification from the FDA outlining criteria required for lifting the clinical hold on U.S. studies of BPX-501. The Company plans to implement revisions to the study protocols, including more comprehensive monitoring and management of neurotoxicity. February 23, 2018